Micofenolato Mofetile Tillomed (Mycophenolate Mofetil)

Mycophenolate mofetil inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), a critical step in the synthesis of guanosine nucleotides. Lymphocytes rely on this pathway for proliferation, so the inhibition limits T‑ and B‑cell expansion, thereby dampening immune responses that cause transplant rejection or autoimmune inflammation.

The dose of Micofenolato Mofetile Tillomed is individualized by the prescribing physician based on the specific transplant protocol, renal function, and patient tolerance. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Mycophenolate mofetil is classified as pregnancy category X because it can cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy, and effective contraception is required for both men and women of reproductive potential. Breastfeeding is not recommended while using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—targeting lymphocyte proliferation rather than cytokine production. It is often used in combination with calcineurin inhibitors to achieve synergistic immunosuppression while allowing lower doses of each agent, potentially reducing toxicity.

The product should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Micofenolato Mofetile Tillomed is taken orally, usually with food or a glass of water to lessen gastrointestinal irritation. The exact timing and frequency are determined by the prescribing clinician and may be adjusted based on therapeutic monitoring.

The most serious adverse events include severe bone‑marrow suppression (leukopenia, anemia), life‑threatening infections, and hepatic toxicity. Patients should be monitored regularly for blood count abnormalities and liver function changes, and any signs of infection should be reported promptly.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in pregnant women, those planning pregnancy without reliable contraception, and individuals with severe uncontrolled infections or significant hepatic impairment.